These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34377682)

  • 21. Respiratory exacerbations in childhood associated with compound heterozygosity Phe508del/Arg117His-7T of the cystic fibrosis transmembrane regulator gene.
    Lee TW; Conway SP; Peckham D; Brownlee KG
    Acta Paediatr; 2008 May; 97(5):670-2. PubMed ID: 18394117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
    Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short communication: novel truncating mutations in the CFTR gene causing a severe form of cystic fibrosis in Italian patients.
    Lenarduzzi S; Morgutti M; Crovella S; Coiana A; Rosatelli MC
    Genet Mol Res; 2014 Nov; 13(4):9636-41. PubMed ID: 25501174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.
    Bergougnoux A; Petit A; Knabe L; Bribes E; Chiron R; De Sario A; Claustres M; Molinari N; Vachier I; Taulan-Cadars M; Bourdin A
    Int J Biochem Cell Biol; 2017 Jul; 88():124-132. PubMed ID: 28478266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Rare Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation Associated With Typical Cystic Fibrosis in an Arab Child.
    Mathew A; Dirawi M; Abou Tayoun A; Popatia R
    Cureus; 2021 Feb; 13(2):e13526. PubMed ID: 33786233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
    Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR
    Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of calpain 1 restores plasma membrane stability to pharmacologically rescued Phe508del-CFTR variant.
    Matos AM; Pinto FR; Barros P; Amaral MD; Pepperkok R; Matos P
    J Biol Chem; 2019 Sep; 294(36):13396-13410. PubMed ID: 31324722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus.
    Petrova NV; Kashirskaya NY; Saydaeva DK; Polyakov AV; Adyan TA; Simonova OI; Gorinova YV; Kondratyeva EI; Sherman VD; Novoselova OG; Vasilyeva TA; Marakhonov AV; Macek M; Ginter EK; Zinchenko RA
    BMC Med Genet; 2019 Mar; 20(1):44. PubMed ID: 30898088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic fibrosis: experience in one institution.
    Liu LC; Shyur SD; Chu SH; Huang LH; Kao YH; Lei WT; Cheng CH; Lo CY; Chen CK; Fang LC
    J Microbiol Immunol Infect; 2014 Aug; 47(4):358-61. PubMed ID: 22992393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.
    Dilokthornsakul P; Patidar M; Campbell JD
    Value Health; 2017 Dec; 20(10):1329-1335. PubMed ID: 29241892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.
    Dekkers JF; Gogorza Gondra RA; Kruisselbrink E; Vonk AM; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    Eur Respir J; 2016 Aug; 48(2):451-8. PubMed ID: 27103391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations.
    Alibakhshi R; Kianishirazi R; Cassiman JJ; Zamani M; Cuppens H
    J Cyst Fibros; 2008 Mar; 7(2):102-9. PubMed ID: 17662673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
    AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
    Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN.
    Merkert S; Bednarski C; Göhring G; Cathomen T; Martin U
    Stem Cell Res; 2017 Aug; 23():95-97. PubMed ID: 28925369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.